Developments in Non-Alcoholic Steatohepatitis (NASH) Drug Discovery


Increasing prevalence of this disease has highlighted the need for new treatment options. Joe Cornicelli, Sr. Director of In Vivo CV and Metabolic Diseases, describes the challenges and opportunities for researchers pursuing new treatments.

Ask us about NASH studies

 

Related Resources